Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Research & Development came in at $267823.0 in Q1 2026, down 54.92% YoY from $594070.0 in Q1 2025, and down 83.83% on a QoQ basis from $1.7 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Research & Development data on file, last reported at $267823.0 in Q1 2026.
- Quarterly Research & Development fell 54.92% year-over-year to $267823.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 53.9% YoY) and the FY2025 annual result came in at $3.1 million, down 51.91% from the prior year.
- Research & Development declined to $267823.0 in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.3 million in Q3 2024 to a low of $267823.0 in Q1 2026.
- A 5-year average of $915996.6 and a median of $831844.0 in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 1766.15% — and 2025, when it sank 87.83%.
- Tracing CNTN's Research & Development over 5 years: stood at $683205.0 in 2022, then soared by 45.3% to $992725.0 in 2023, then jumped by 110.07% to $2.1 million in 2024, then declined by 20.6% to $1.7 million in 2025, then slumped by 83.83% to $267823.0 in 2026.
- The last three Research & Development figures came in at $267823.0 (Q1 2026), $1.7 million (Q4 2025), and $277803.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 267,823.00 |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 277,803.00 |
| Jun 30, 2025 | 123,638.00 |
| Mar 31, 2025 | 594,070.00 |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 999,553.00 |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 992,725.00 |
| Sep 30, 2023 | 488,177.00 |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 683,205.00 |
| Sep 30, 2022 | 831,844.00 |
| Jun 30, 2022 | 455,546.00 |
| Mar 31, 2022 | 307,829.00 |
| Dec 31, 2021 | -41,005.00 |
| Sep 30, 2021 | 313,133.00 |
| Jun 30, 2021 | 674,765.00 |